Dissolution in suitable solvent (e.g., water + acetonitrile) Reduction and alkylation (if disulfide bonds are present) Enzymatic digestion (optional for bottom-up sequencing approach) Key Insight: Clean and well-prepared samples significantly reduce noise and improve detection sensitivity
Addiction and Craving Reduction: Rewiring the Reward System With as much excitement for off-label use of GLP-1RAs, it appears the most exciting finding may be in the treatment of substance use disorders
(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kalpha inhibitors in breast cancer
To receive the maximal benefits from BPC-157 it is recommended to take for 12 weeks, with a one month break, then treatment can be restarted
